Therapy Areas: Oncology
Cantargia reports early remission data from nadunolimab trial in MDS and AML
27 April 2026 - Swedish biotechnology company Cantargia AB (STO:CANTA) on Monday reported early results from an ongoing Phase 1b/2a trial evaluating nadunolimab in combination therapies for high-risk ...
WuXi Biologics announces structural completion and key equipment arrival at Chengdu microbial manufacturing site
27 April 2026 - WuXi Biologics (HK:2269), a China-based, global Contract Research, Development and Manufacturing Organisation (CRDMO), announced on Friday the structural completion and key equipment a...
HanchorBio chooses Bloomberg to enhance strategic intelligence across drug development and global biopharma
27 April 2026 - HanchorBio Inc (TPEx:7827), a Taiwan-based global clinical-stage biotechnology company advancing next-generation immunotherapies for immuno-oncology and immune-related diseases, announ...
Servier completes Day One Biopharmaceuticals acquisition
24 April 2026 - French pharmaceutical company Servier announced on Thursday the successful completion of its tender offer to acquire all of the issued and outstanding shares of common stock of Day One...
Apotex and Cumberland Pharmaceuticals to integrate their US branded businesses
24 April 2026 - Canadian pharmaceutical company Apotex Inc and Cumberland Pharmaceuticals Inc, a US-based specialty pharmaceutical company, announced on Thursday that they have entered into a strategi...
Orion Pharma launches Phase 1b/2 TEADCO trial of ODM-212 in advanced solid tumours
23 April 2026 - Finnish pharmaceutical company Orion Corporation (Orion Pharma) (HEL:ORNBV) said on Thursday that it has initiated the TEADCO Phase 1b/2 basket trial evaluating ODM-212, an oral pan-TE...